Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
One small molecule for man, one giant leap for mankind with obesity.
Med. 6:100924 (2025)
The ATTAIN-1 trial launches a new era in obesity care. Orforglipron, the first oral small-molecule GLP-1 receptor agonist to complete a phase 3 clinical trial, delivers meaningful reductions in body weight and improvements in metabolic health. This advancement moves beyond peptide-based injectables, paving the way for potent obesity therapies that are simpler, more affordable, and accessible to millions worldwide.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Editorial
ISSN (print) / ISBN
2666-6359
e-ISSN
2666-6340
Journal
Med (N Y)
Quellenangaben
Volume: 6,
Issue: 12,
Article Number: 100924
Publisher
Elsevier
Publishing Place
50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes and Obesity (IDO)
Grants
German Center for Diabetes Research (DZD e.V.)
German Research Foundation
European Union within European Research Council ERC-CoG
German Research Foundation
European Union within European Research Council ERC-CoG